NMRA Stock Price | Neumora Therapeutics, Inc. P/E, Revenue, EPS, & Forecasts

Neumora Therapeutics, Inc. • NMRA

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Neumora Therapeutics, Inc.

Ticker

NMRA

Trading on

NASDAQ

ISIN

US6409791000

Industry

Biotechnology

Sector

Healthcare

CEO

Headquarters

490 Arsenal Way, Watertown, MA, United States, 02472

Employees

Website

neumoratx.com

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Metrics

BasicAdvanced

Market cap

$478M

P/E ratio

EPS

-$1.47

Dividend Yield

0.00%

Beta

3.03

Forward P/E ratio

EBIDTA

$-264M

Ex dividend date

Price & volume

Market cap

$478M

Average daily volume

3.2M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

3.48

Earnings

EPS

-$1.47

EPS estimate (current quarter)

-$0.34

EPS estimate (next quarter)

-$0.34

EBITDA

$-264M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

3.03

52-week High

$11.77

52-week Low

$0.61

50-day moving average

$2.01

200-day moving average

$1.42

Short ratio

12.48

Short %

11.56%

Management effectiveness

ROE (TTM)

-89.37%

ROA (TTM)

-52.63%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

167M

Float

84.1M

Insiders %

27.55%

Institutions %

54.71%

Analyst Insights & forecasts

38% Buy

62% Hold

0% Sell

Based on information from 8 analysts.

Average price target

$8.50

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.37

-$0.62

40.32%

Q4 • 24Beat

-$0.42

-$0.46

8.70%

Q1 • 25Beat

-$0.33

-$0.45

26.67%

Q2 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-52.7M

-∞%

Q2 • 25

$0M

$-56.8M

-∞%

Q3 • 25

NaN%

7.63%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$224M

$40.9M

18.29%

Q2 • 25

$178M

$45.7M

25.68%

Q3 • 25

-20.55%

11.54%

40.39%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-52.4M

$30.4M

$18.5M

$-52.4M

Q2 • 25

$-46.6M

$51.3M

$-0.1M

$-46.6M

Q3 • 25

-11.01%

68.82%

-100.74%

-10.98%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Neumora Therapeutics, Inc. share?

Neumora Therapeutics, Inc. shares are currently traded for undefined per share.

How many shares does Neumora Therapeutics, Inc. have?

Neumora Therapeutics, Inc. currently has 167M shares.

Does Neumora Therapeutics, Inc. pay dividends?

No, Neumora Therapeutics, Inc. doesn't pay dividends.

What is Neumora Therapeutics, Inc. 52 week high?

Neumora Therapeutics, Inc. 52 week high is $11.77.

What is Neumora Therapeutics, Inc. 52 week low?

Neumora Therapeutics, Inc. 52 week low is $0.61.

What is the 200-day moving average of Neumora Therapeutics, Inc.?

Neumora Therapeutics, Inc. 200-day moving average is $1.42.

Who is Neumora Therapeutics, Inc. CEO?

The CEO of Neumora Therapeutics, Inc. is -.

How many employees Neumora Therapeutics, Inc. has?

Neumora Therapeutics, Inc. has 96 employees.

What is the market cap of Neumora Therapeutics, Inc.?

The market cap of Neumora Therapeutics, Inc. is $478M.

What is the P/E of Neumora Therapeutics, Inc.?

The current P/E of Neumora Therapeutics, Inc. is null.

What is the EPS of Neumora Therapeutics, Inc.?

The EPS of Neumora Therapeutics, Inc. is -$1.47.

What is the PEG Ratio of Neumora Therapeutics, Inc.?

The PEG Ratio of Neumora Therapeutics, Inc. is null.

What do analysts say about Neumora Therapeutics, Inc.?

According to the analysts Neumora Therapeutics, Inc. is considered a hold.